Kadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life sciences, situated on the Campus Grand Parc in Villejuif.

A global biotechnology company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries

ACROBiosystems was founded in 2010 with a clear purpose: to become an indispensable partner to the global biopharmaceutical industry. The company today employs close to 1,000 people across offices, R&D centres, and production facilities spanning Europe, North America and Asia, serving thousands of customers worldwide including leading pharmaceutical and biotechnology companies, CRO/CDMOs, and academic institutes. Its portfolio covers the full drug development continuum — from recombinant proteins, antibodies, and assay kits to GMP-grade custom and scientific services — organised around dedicated brands including Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others, with a particular focus on oncology, cell and gene therapy, and immunotherapeutics, and their clinical applications. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Global reach, local ground: A step into the Campus Grand Parc oncology ecosystem

ACROBiosystems' arrival at The HIVE takes the form of a dedicated office space within the Innovation Center, a deliberate step designed to establish a local presence and build connections within the Campus Grand Parc community. Home to biotechs, hospitals, translational research institutes, and clinical partners, this ecosystem represents exactly the kind of environment where the company can draw on its global reach to engage directly with the teams developing the next generation of cancer therapies. As a member of the Paris-Saclay Cancer Cluster (PSCC) since 2025, ACROBiosystems has already begun building connections within the region's life sciences community — a presence that its new hub at The HIVE is designed to further strengthen.

A hub shaped for collaboration and proximity

The HIVE Innovation Center brings together life sciences companies of all sizes under one roof, creating the conditions for the kind of day-to-day interactions that formal partnerships alone cannot generate. For ACROBiosystems, whose value proposition is built on being a trusted partner from discovery to the clinic, this proximity to an active scientific community is precisely what makes The HIVE a fitting base for its French operations.

Mike Chen, Chairman, Founder & CEO of ACROBiosystems, said, "France — and the Paris-Saclay region in particular — sits at the convergence of world-class scientific research, clinical excellence, and a rapidly maturing biotech community. Deepening our presence at The HIVE puts us exactly where our partners live and work. Our role is to be the dependable backbone behind their science — bringing reliable quality, integrated innovation, and considerate service from discovery through to the clinic. We're here not just to open an office, but to plug into this ecosystem, listen, collaborate, and grow alongside the teams working to deliver tomorrow's therapies across oncology, immuno-oncology, advanced therapies, and beyond."

"We are proud that ACROBiosystems has chosen Campus Grand Parc and The HIVE to deepen its French operations. This is a strong signal of the ecosystem's growing global attractiveness," declared Sandrine Lo, Investment & Asset Manager Kadans Science Partner.